Bank of Montreal Can Boosts Holdings in ADMA Biologics Inc $ADMA

Bank of Montreal Can grew its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 18.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,269 shares of the biotechnology company’s stock after purchasing an additional 6,466 shares during the period. Bank of Montreal Can’s holdings in ADMA Biologics were worth $770,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ purchased a new stake in ADMA Biologics in the first quarter worth about $35,000. SVB Wealth LLC bought a new position in shares of ADMA Biologics in the 1st quarter worth approximately $35,000. Cullen Frost Bankers Inc. lifted its stake in shares of ADMA Biologics by 112.5% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares during the period. Toth Financial Advisory Corp boosted its position in shares of ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 2,293 shares in the last quarter. Finally, Ameritas Advisory Services LLC bought a new stake in shares of ADMA Biologics during the second quarter valued at approximately $46,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Down 0.9%

ADMA Biologics stock opened at $15.56 on Monday. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of 18.09 and a beta of 0.40. The business’s fifty day simple moving average is $15.24 and its two-hundred day simple moving average is $17.57. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $134.22 million during the quarter, compared to the consensus estimate of $131.20 million. During the same period last year, the company earned $0.15 earnings per share. The company’s revenue was up 12.0% on a year-over-year basis. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.